
|Articles|February 15, 2004
B&L finishes purchase of new fluoroquinolone
Rochester, NY-Bausch & Lomb has completed the purchase of InSite Vision's ISV-403 compound for the treatment of ocular infections. Bausch & Lomb gave InSite Vision an undisclosed cash sum and reimbursement of certain product development expenses. In exchange, InSite Vision will give Bausch & Lomb a percentage of future product sales in all licensed countries.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
New optoretinography technique allows direct measurement of rod function in vivo
2
Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
3
First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
4
FDA grants breakthrough therapy designation to Oculis’ privosegtor for optic neuritis
5












































